Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers
- PMID: 1009518
Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their beta anomers
Abstract
Four new derivatives of daunorubicin, characterized by the absence of the methoxyl group at the C-4 position, have been obtained by chemical synthesis. 4-Demethoxydaunorubicin (NSC-256439) was effective against L1210 and Gross leukemias and ascites and solid Sarcoma 180 at doses four to eight times lower than those effective for daunorubicin. The beta anomer of 4-demethoxydaunorubicin was active at doses 13and eight times higher than those of its corresponding alpha anomer against L1210 and Gross leukemias respectively. 4-Demethoxy-7,9-diepidaunorubicin and its beta anomer were devoid of any biologic activity at the doses tested.
Similar articles
-
Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin.Cancer Res. 1977 Dec;37(12):4523-8. Cancer Res. 1977. PMID: 922737
-
Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4' -epiadriamycin.Cancer Treat Rep. 1978 Mar;62(3):375-80. Cancer Treat Rep. 1978. PMID: 647696
-
Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.Cancer Res. 1983 Jun;43(6):2880-3. Cancer Res. 1983. PMID: 6573953
-
Antileukemic activity of 4-demethoxydaunorubicin in mice.Tumori. 1980 Oct 31;66(5):549-64. doi: 10.1177/030089168006600503. Tumori. 1980. PMID: 6936969
-
Effect of various substitutions in positions 1, 2, 3, and 4 of 4-demethoxydaunorubicin and 4-demethoxyadriamycin.Cancer Chemother Pharmacol. 1978;1(4):249-54. doi: 10.1007/BF00257158. Cancer Chemother Pharmacol. 1978. PMID: 750112
Cited by
-
Antineoplastic drugs: clinical pharmacology and therapeutic use.Drugs. 1978 Jul;16(1):46-87. doi: 10.2165/00003495-197816010-00003. Drugs. 1978. PMID: 78795 Review. No abstract available.
-
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs. 1991 Oct;42(4):690-719. doi: 10.2165/00003495-199142040-00010. Drugs. 1991. PMID: 1723369 Review.
-
Oral idarubicin. A review of its pharmacological properties and clinical efficacy in the treatment of haematological malignancies and advanced breast cancer.Drugs Aging. 1997 Jul;11(1):61-86. doi: 10.2165/00002512-199711010-00006. Drugs Aging. 1997. PMID: 9237041 Review.
-
Potential role of oral anthracyclines in older patients with cancer.Drugs Aging. 1994 May;4(5):392-402. doi: 10.2165/00002512-199404050-00004. Drugs Aging. 1994. PMID: 8043941 Review.
-
Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer.Cancer Chemother Pharmacol. 1987;20(1):75-7. doi: 10.1007/BF00252964. Cancer Chemother Pharmacol. 1987. PMID: 3040287 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Miscellaneous